APCARI - Key Persons
Adam Kinnaird is a Surgeon, Scientist, Chair of APCaRI, and the Frank and Carla Sojonky Chair in Prostate Cancer Research, in the Division of Urology, Department of Surgery at the University of Alberta. The Sojonky Chair was endowed to the Alberta Cancer Foundation by the late Frank Sojonky and a team of volunteers known as the Bird Dogs and supports research that will help us better understand, diagnose, and treat prostate cancer. Adam completed a fellowship in Imaging, Targeted Biopsy, and Focal Therapy for Prostate Cancer at UCLA. His lab studies translational prostate cancer research with a focus on new drugs, technologies, and devices. He was a varsity athlete and graduate of the University of Alberta, having won two national championships while he was a member of the Golden Bears men's ice hockey team. Adam completed his MD and Urology residency at the U of A, during which he was enrolled in the Clinician Investigator Program. He completed his PhD as a Vanier Scholar and was awarded the Governor General's Gold Medal in research. Adam has published in high-impact journals such as Nature Reviews Cancer, Cell, and European Urology and has been awarded funding from local, regional, and national grant competitions since starting as an Assistant Professor in November 2020
Job Titles:
- Division of Urology, Department of Surgery, University of Alberta / Alberta Urology Institute
- Division of Urology, Department of Surgery, University of Alberta View Profile
Dr. Fairey received his MD at the University of Alberta in 2006 and completed his residency in Urologic Surgery at the University of Alberta and fellowship training in Urologic Oncology at the University of Southern California/Norris Comprehensive Cancer Center. Dr. Fairey's main areas of expertise include radical surgical procedures for bladder, prostate, and kidney cancers as well as reconstructive surgery of the lower urinary tract following radical cystectomy or pelvic exenteration. He has a special interest in function-sparing procedures (including advanced reconstructive techniques that re-create the natural urination pathway after bladder removal - continent urinary diversion) to optimize quality of life after surgery. Dr. Fairey is actively involved in clinical and translational research studies in patients with bladder, prostate, and kidney cancers.
Job Titles:
- STIR ), FRCPC ( Diagnostic Radiology ), FRCPC ( Nuclear Medicine )
Dr. Tamm completed his undergraduate degree (2010), medical degree with special training in research (2011) and residency programs in both radiology (FRCPC, 2016) and nuclear medicine (FRCPC, 2018) at the University of Alberta. He is practicing as a combined nuclear medicine physician and radiologist and is the program director for the combined nuclear medicine and radiology residency program at the University of Alberta.
Job Titles:
- Clinical Research Coordinator, APCaRI, Department of Oncology, University of Alberta Anaïs [ ]
- Department of Oncology / University of Alberta
Job Titles:
- Launching and Academic Research Career. Dis Model Mech. 2009 Nov - Dec 2 ( 11 - 12 )
- Research Group
Cho, C.F., Ablack, A., Leong, H.S., Zijlstra, A., Lewis, J.D. (2011) Evaluation of nanoparticle uptake in tumors in real time using intravital imaging. Journal of Visualized Experiments 52: doi: 10.3791/2808. (Highlighted in Biotechniques, May 2012)
Andries Zijlstra, John Lewis, Bernard DeGryse, Heidi Stuhlmann, and James P. Quigley (2008) The inhibition of tumor cell intravasation and subsequent metastasis through the regulation of in vivo tumor cell motility by the tetraspanin CD151, Cancer Cell, March 13 (3) pp. 221-34. (PMID: 18328426)
Choi-Fong Cho, Amber Ablack, Hon-Sing Leong, Andries Zijlstra, and John Lewis. (2011) Evaluation of nanoparticle uptake in tumors in real time using intravital imaging. Journal of visualized experiments : JoVE, (52), e2808. (PMID: 21730939)
Aparicio-Ting FE, Friedenreich CM, Kopciuk KA, Plotnikoff RC, Bryant HE. Prevalence of meeting physical activity guidelines for cancer prevention in Alberta. Chronic Dis Inj Can. 2012 Sep;32(4):216-26.
Job Titles:
- Department of Oncology / University of Alberta
- Research Associate, Dr. John Lewis Laboratory, Department of Oncology, University [ ]
2. Lynes E, Raturi A , Ortiz C , Simmen T et al, 2013, Palmitoylation is the switch that assigns calnexin to quality control or ER calcium signaling. J Cell Sci, 2013 Sep 3893-903
J. Al-Hourani, M. I. El-Barghouthi, R. McDonald, W. Al-Awaida, F. Wuest. Docking studies and the crystal structure of two tetrazole derivatives: 5-(4-chlorophenyl)-1-{4-(methylsulfonyl)phenyl}-1H-tetrazole and 4-{5-(4-methoxyphenyl)-1H-tetrazol-1-yl}benzene-sulfonamide. J. Mol. Struct. 2015, 1101, 21-27.
J. Al-Hourani, R. McDonald, M. I. El-Barghouthi, W. Al-Awaida, S. Sharma, F. Wuest. Molecular Docking Studies and X-ray Structure Determination of 1-{4-(Methylsulfonyl)phenyl}-5-phenyl-1H-tetrazole. Jordan J. Chem. 2015, 10, 34-40.
B. J. Al-Hourani, S. Sharma, J. Y. Mane, J. Tuszynski, V. Baracos, T. Kniess, M. Suresh, J. Pietzsch, F. Wuest. Synthesis and evaluation of 1,5-diaryl-substituted tetrazoles as novel selective cyclooxygenase-2 (COX-2) inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 1823-1826.
Job Titles:
- Department of Laboratory Medicine and Pathology, University of Alberta
Dr. Adam received his B.Sc in Pharmacology in 2007 at the University of Alberta. He also studied Medicine at the University of Alberta and completed his MD in 2011. He is presently a resident in Anatomical Pathology at the University of Alberta. Dr. Adam is the recipient of several prestigious awards, including the John James Ower Medal and Scholarship in Pathology, the Isaac and Leah Weinlos Prize in Pathology, the Merck Sharp and Dohme Prize in Therapeutics through the University of Alberta.
Daniel Heng, Wanling Xie, Meredith M. Regan, Mark A. Warren, Ali Reza Golshayan, Chakshu Sahi, Bernie Eigl, Dean Ruether, Tina Cheng, Scott North, Peter Venner, Jennifer J. Knox, Kim N. Chi, Christian Kollmannsberger, David F. McDermott, William K. Oh, Michael B. Atkins, Ronald M. Bukowski, Brian I. Rini, Toni K. Choueiri. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. Journal of Clinical Oncology, 27(34), 5794-99. 2009.
Job Titles:
- Department of Oncology / University of Alberta
- Postdoctoral Fellow, Dr. John Lewis Laboratory, Department of Oncology, University
Job Titles:
- Assistant Professor, Applied Biostatistician University of Alberta, Edmonton, AB Dr. [ ]
Dr. Broadhurst completed his PhD training in Biostatistics and Machine Learning at the University of Wales in Aberystwyth, UK in 1997. Dr. Broadhurst is an internationally recognized expert specializing in Experimental Design (DoE), Signal Processing, Statistics, Multivariate Data Analysis, Data Visualization, and Bioinformatics. He investigates metabolomics-the systematic, and data-driven, study of temporal interactions between the compliment of low molecular weight (bio)chemicals (metabolites) abundant within living organisms, tissues and cells. His research focuses on the development of expert systems merging clinical and ‘omic biomarker (genomics; transcriptomics; proteomics; metabolomics) measurements into clinically relevant diagnostic tools. Translating basic science into personalized (or precision) medicine.
Dr. Ruether is a medical oncologist at the TBCC who has worked in the GU program for 20 years.
His undergraduate training was done at the university of Calgary and medical school completed at the University of Alberta. Post graduate training in internal medicine, hematology and medical oncology was completed at the University of Calgary.
As the leader of the local and provincial GU program Dr Ruether has played an important role in bringing clinical research trials for patients with all stages of prostate cancer to Alberta. He is also responsible for the development of an educational program run through the prostate cancer center in Calgary for patients and their families dealing with a new diagnosis of prostate cancer.
Job Titles:
- Department of Oncology / University of Alberta
- Research Associate, Dr. John Lewis Laboratory, Department of Oncology, University [ ]
Job Titles:
- Department of Oncology / University of Alberta / Edmonton
Job Titles:
- Member of the Division of Urology
Dr Michael Chetner is a member of the Division of Urology and a Clinical Professor in the Department of Surgery, in the Faculty of Medicine and Dentistry at the University of Alberta. He completed his urology residency at the University of Alberta, during which time he completed his Masters in Science in Experimental Surgery focusing on photodynamic therapy in a rat prostate cancer model. He did his "Fellowship" training in Seattle at the Veteran's Administration Medical Center (VMAC) and at the University of Washington under Dr. M.K. Brawer, Dr Paul H. Lange & Dr Michael E. Mayo in the fields of continent urinary diversion and the diagnosis and management of prostate cancer. He has been a practicing urologist in Edmonton since 1991. His current clinical practice focuses on both benign and malignant prostate disease (Minimally Invasive Surgery) and uro-oncology. His current research activities are focused on clinical trials in BPH and prostate cancer.
He is the past Divisional Director of Urology in the Department of Surgery at the University of Alberta (1995 - 2010). Past Secretary of the Canadian Urological Association ( CUA, 1997-2002), past Executive Committee Member of the CUA (President 2012). Past President of the Alberta Society of Urology (ASU - 1991-1996). Executive Committee Member of the Canadian Uro-Oncology Group (CUOG - 1992-1998), Treasurer of CUOG (1996-1998). Member of the Canadian Council of University Urologic Chairs (CCUUC - 1996-2010, Chair of CCUUC, 2002-2008). Nucleus Member and Test Committee Member, Royal College of Surgeons of Canada (RCSC) on Principles of Surgery (1992-1995), Test Committee and Examination Board in Urology Royal College of Surgeons of Canada (RCSC - 1994-1999). Contributing Editor and Editorial Board Member (reviewer) on multiple national and international Journals and publications.
Dr. Bimal Bhindi is a urologic oncologist at the Southern […]
Job Titles:
- Department of Agricultural, Food and Nutritional Science, University of Alberta
- Expert
- Professor at the University of Alberta
- Professor, Department of Agricultural, Food and Nutritional Science, University of [ ]
Dr. Carla Prado is a Professor at the University of Alberta in Canada, and a Campus Alberta Innovates (CAIP) Chair in Nutrition, Food, and Health. She is the Director of the Human Nutrition Research Unit, a state-of-the-art research, and training facility that supports cutting-edge research on the physiology and causes of nutritional problems through assessment of body composition, whole body energy metabolism, diet, and physical activity.
Dr. Prado is an expert in assessing nutritional status through the precise measurement of body composition and energy metabolism. Her research has shown for the first time the prevalence and clinical implications of sarcopenic obesity (concurrent appearance of low muscle and high fat) in cancer and has provided evidence of the independent effect of body composition on cancer recurrence, treatment, and survival. The focus of her current research program is to develop targeted nutrition interventions for the prevention and treatment of sarcopenia and sarcopenic obesity in patients with cancer.
Dr. Prado received her Ph.D. from the University of Alberta, Canada, and has completed further training at the Cross Cancer Institute (Canada), the National Institutes of Health (USA), and Newcastle University (UK). She is an Associate Editor of Clinical Nutrition and the Journal of Cachexia, Sarcopenia and Muscle. For Dr. Prado's full bio please check www.drcarlaprado.com.
Job Titles:
- Clinical Assistant Professor
- Department of Surgical Oncology / University of Calgary
Dr. Eric Hyndman is a clinical assistant professor of urology who subspecializes in minimally invasive, robotic and open surgical treatment of urologic malignancies. He started his medical career the University of Calgary and obtained his PhD in medical sciences investigating cardiovascular genetics. He then completed his medical degree in Calgary after which he travelled north to Edmonton for his Urology residency. He then continued his studies by completing a fellowship at Johns Hopkins in Urologic Oncology. He is now an active Urologic Surgeon at the Southern Alberta Institute of Urology.
Dr. Hyndman also has an active and expanding research program investigating the both prostate and bladder cancers. In particular he leads the active surveillance program in Calgary and within this population is trying to determine what causes progression to an aggressive disease.
Dr. Frank Wuest studied chemistry at Technical University of Merseburg and Dresden University of Technology in Germany. He obtained his PhD in the field of radiopharmaceutical sciences in 1999. After his PhD, he did a post-doc with Dr. Michael Welch at the School of Medicine in St. Louis where he dealt with radiolabeled fatty acids for cardiac research. After his return to Germany in 2001, Dr. Frank Wuest became head of the PET Tracer Division of the Research Centre Dresden-Rossendorf. From 2001-2006 he was also head of the junior research group "Radiopharmceutical Chemistry" of the Research Centre Dresden-Rossendorf. Frank Wuest accomplished his habilitation thesis in biochemistry at Dresden University of Technology in 2006, where he also obtained the venia legendi for biochemistry. In 2008 he started as the Dianne and Irving Kipnes Chair in Radiopharmaceutical Sciences in the Department of Oncology at the University of Alberta. He was member of the local and international scientific committee for the organisation of the 18th ISRS meeting in Edmonton in 2009.
Dr. Wuest's research interests are embedded in the multidisciplinary field of translational cancer research with special focus on the design, synthesis and radiopharmacological characterization of novel radiopharmaceuticals to optimize current diagnosis and treatment of cancer. Research activities are aimed at the evaluation and translation of the diagnostic and therapeutic potential of novel molecular targets and specific biochemical signatures associated with the development and progression of cancer. This especially involves the use of PET radiopharmaceuticals and pre-clinical small animal PET imaging for non-invasive assessment of cancer-related metabolic pathways and biochemical processes at the cellular and molecular level. Current research activities include (1) the design, synthesis and characterization of novel molecular probes for targeting cyclooxygenase-2 (COX-2) and neuropeptide receptors in cancer, (2) the assessment and characterization of novel molecular targets for translational cancer research like GLUT5 and (3) the application of novel technologies for molecular imaging and therapy of cancer.
Dr. Jack Tuszynski heads a multi-disciplinary team creating "designer drugs" for cancer chemotherapy using computational biophysics methods. To make advances in this new promising field of biophysical modeling, Jack Tuszynski drew on his physics background to create computer software programs that screen proteins against chemical compounds to find the perfect match based on the lock and key principle. The goal of Tuszynski's computational biophysics work is to create optimized drugs that would target cancerous cells with minimal side-effects to the healthy cells. Dr. Tuszynski's research interests are strongly linked to the protein tubulin and the microtubules assembled from it. These have been studied using methods ranging from simple stochastic models to detailed molecular dynamics computer simulations, as well as through laboratory manipulations of living cells. Due to its prominent role played in eukaryotic cell division, tubulin is an important target for anti-cancer cytotoxic treatments. His on-going research aim is to identify variants of known compounds showing greater tubulin isotype-specific effects. These compounds could potentially lead to more efficacious chemotherapy treatments with lower side effects. The group has also examined microtubule's biochemical, electrical, structural, and mechanical properties; proteins that bind to microtubules (MAPs); and the motor proteins in cells that travel along microtubules and actin filaments. Over the past few years, one of the main research interests in the Tuszynski lab has been the creation of 3D models of p53 and its mutants as well as a search for activators of its mutants. Several papers on this work have already been published in peer-review journals. His group is also developing physiologically-based models and simulations for pharmacokinetic and pharmacodynamic applications. Currently, he has been focused in his work on the discovery and optimization of novel chemotherapy agents and methods of their administration.
Dr. Lauren Walker earned her PhD in clinical psychology from the University of Calgary in 2013. She completed a Clinical Fellowship specializing in Oncology and Sexuality in the Department of Oncology at the University of Calgary and Tom Baker Cancer Centre. During this fellowship she gained expertise in providing counseling to patients experiencing sexual difficulties after cancer treatment. She also completed a brief externship providing her with clinical training from the University of British Columbia Sexual Medicine Program.
Dr. Walker is a registered psychologist in the province of Alberta, and holds an academic appointment as a Research Assistant Professor in the Department of Oncology, Division of Psychosocial Oncology, at the University of Calgary. Dr. Walker earned her PhD in Clinical Psychology from the University of Calgary in 2013, where she evaluated a patient education initiative for preparing prostate cancer patients and their partners for undergoing androgen deprivation therapy (ADT).
She currently runs several programs at the Prostate Cancer Centre in Calgary include an Intimacy after Prostate Cancer Workshop for men and their partners. Dr. Walker provides sexual counseling to all types of cancer patients seeking treatment at the Tom Baker Cancer Centre.
Dr. Walker is an active researcher and has contributed over 20 publications to the scientific peer reviewed literature about psychosocial and sexual adaption to prostate cancer treatments. She is also part of the leadership of the TrueNth Survivorship initiatives funded by Movember and Prostate Cancer Canada - in the areas of ADT and sexual health. She is an active collaborator with Canadian experts in the field and has contributed to the development of sexual health curriculum to train future health care professionals in sexuality and oncology.
She also helps to lead the OASIS - Oncology and Sexuality, Intimacy and Survivorship -program out of the Tom Baker Cancer Centre. This is a provincial sexual health service for patients that have been through cancer treatment.
Job Titles:
- Department of Oncology / University of Calgary
- Director of Cancer Surveillance and Reporting, C - MORE, Alberta Health Services, [ ]
- Is Director of Surveillance
Dr. Lorraine Shack is Director of Surveillance and Reporting, CancerControl Alberta, Alberta Health Services and holds and adjunct joint appointment in Oncology and Community Health Sciences, University of Calgary. She joined AHS in 2009 (formerly Cancer Board) from the National Health Service, UK where she lead cancer surveillance activities for the North West Cancer Intelligence Service. Dr Shack's research interests include cancer survival measures, patient treatment pathways and use of administrative health data.
Dr. Matthew Parliament is full Professor, Division of Radiation Oncology, Department of Oncology at the University of Alberta and Medical Director (interim) of the Cross Cancer Institute. The Division is active in all facets of cancer research, from basic discovery science, to pre-clinical studies, to translational science including biomarker discovery, and finally full scale human clinical trials. The academic oncology environment at the Cross Cancer Institute (an integrated stand-alone comprehensive cancer centre) ranks among the top oncology centres in Canada, and is consistently regarded highly from a national and international perspective for co-operative group clinical trial accrual and innovation.
Job Titles:
- Broadhurst DI, Ellis DI, Goodacre R, Kell DB
F. Graf, F. Wuest Allan GM, J. Pietzsch. Cyclin-Dependent Kinases (Cdk) as Targets for Cancer Therapy and Imaging. Advances in Cancer Therapy, Hala Gali-Muhtasib (Ed). 2011, 265-288.
J. Way, V. Bouvet, F. Wuest. Application of palladium-mediated cross-coupling reactions for the synthesis of 18F-labeled compounds. Curr. Org. Chem. 2013, 17, 2138-2152.
V. Bouvet, M. Wuest, F. Wuest. Copper-free click chemistry with the short-lived positron emitter fluorine-18.
M. Pretze, F. Wuest, T. Peppel, M. Köckerling, C Mamat. The Traceless Staudinger Ligation with Fluorine-18: A Novel and Versatile Labeling Technique for the Synthesis of Radiotracers for Positron Emission Tomography (PET). Tetrahedron Lett. 2010, 51, 6410-6414.
J. Pietzsch, F. Wuest. Fluorine-18 radiolabelling of native and oxidized proteins: An important tool in the pathophysiologists' toolbox. Chemistry Today. 2009, 27, 12-14.
Job Titles:
- Assistant Clinical Professor Department of Laboratory Medicine and Pathology University [ ]
- Department of Laboratory Medicine and Pathology / University of Alberta
Dr. Siadat is a Genitourinary and Anatomical Pathologist with Alberta Health Services.
He received his training in Anatomical Pathology in Ottawa and completed a fellowship in Genitourinary Pathology at Toronto General Hospital. He is the leading genitourinary pathologist in Edmonton, with special interest in architectural patterns in prostate cancer, kidney tumors, and use of machine learning in anatomical pathology.
He is an avid advocate for role of pathologists in multidisciplinary cancer management.
Fred Saad, Dean Ruether, Scott Ernst, Scott North, Tina Cheng, Paul Perrotte, Pierre Karakiewicz and Eric Winquist. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone. BJU Int.;102(5):551-5. Jan 31, 2008.
Dr. Wong got his Ph.D. in experimental low temperature physics from Cornell University in 1990. After a few years at the California Institute of Technology he was recruited to the Human Genome Project (HGP) by Maynard Olson at the University of Washington. As the project reached its crescendo in the late 1990's, he accepted an invitation from Jian Wang, Huanming Yang, and Jun Yu to help launch what eventually became BGI-Shenzhen. In 2007 he returned home to Canada, and specifically to the University of Alberta, where he is now a Professor in Biological Sciences, a Professor in Medicine, and the iCORE Chair in Biosystems Informatics. From this position he has launched two new programs: one to sequence the transcriptomes of 1000 plants, and another to develop methodologies to detect novel infectious agents in chronic human diseases.
Job Titles:
- Department of Surgery / University of Calgary
Dr. Gotto is a Uro-Oncologist specializing in the surgical management of urologic malignancies, including prostate cancer. After graduating from the University of British Columbia and receiving the Wesbrook Scholar designation and Hamber Scholarship in Medicine, Dr. Gotto completed his residency training in the Department of Urologic Sciences at UBC. He went on to complete the prestigious Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York. He received his Masters of Public Health from Harvard with a focus in clinical effectiveness research. He has a large clinical practice at the Southern Alberta Institute of Urology and is an Assistant Professor in the Department of Surgery at the University of Calgary and a member of both the Division of Urology and the Division of Surgical Oncology. He is the Surgical Outcomes Leader for the Southern Alberta Institute of Urology and sits on the Alberta Provincial GU Tumour Team Executive. His research interests lie in health outcomes and clinical effectiveness research as well in translational studies. Dr. Gotto received the Canadian Urological Association scholarship for his research into health outcomes reporting and synoptic data acquisition
Dr. Todd completed both his medical training and his residency in Urology at the University of Alberta. His interests are renal transplantation, urologic oncology and surgical education.
Dr. Vogel has been appointed as Full Professor of biochemistry at the University of Calgary since 1991, where he also directs the local bio-NMR centre. He has been the academic leader of the academic Metabolomics Research Centre since its inception in 2006. His research interests include the application of protein chemistry and molecular biology methods, used in combination with high-resolution NMR spectroscopy. Using these methods, Dr. Vogel's lab examines protein and peptide structures as well as their functional properties. They focus on several proteins, such as calcium-binding regulatory proteins, bacterial proteins mediating iron-uptake, and anti-microbial peptides. Dr. Vogel has expertise in metabolic profiling biomarker discovery and has been involved many metabolomics studies in several areas such as infectious diseases and cancer.
Vogel, H.J. (2010) "Iron-uptake in Gram-negative bacteria and the battle for iron" Bulletin of the Canadian Society for Biochemistry, Molecular and Cell Biology, 29-35.
Haney, E.F., Nazmi, K., Bolscher, J.G.M. and Vogel, H.J. (2012) "Structural and biophysical characterization of an antimicrobial peptide chimera comprised of lactoferricin and lactoferrampin" Biochem. Biophys. Acta - Biomembranes 1818: 762-775.
Macdonald, J.A., Ishida, H., Butler, T.J., Ulke-Lemee, A., Chik, J. and Vogel, H.J. (2012) "The intrinsically disordered N-terminus of CHASM interacts with the calponin homology domain to provide an interface for tropomyosin binding" Biochemistry 51: 2694-2705.
Schicho, R., Nazyrova, A., Shaykhutdinov, R., Vogel, H.J. and Storr, M. (2012) "Quantitative metabolomic profiling of serum, plasma and urine by 1 H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals" J. Proteome Res. 11: 3344-3357.
Haney, E.F., Nguyen, L.T., Schibli, D.J. and Vogel, H.J. (2012) "Design of novel tryptophan-rich membrane-active antimicrobial peptides from the membrane-proximal region of the HIV glycoprotein gp41" Beilstein J. Org. Chem. 8: 1172-1184.
Reimer, R.A., Maurer, A.D., Eller, R.K., Hallam, M.C., Shaykhutdinov, R., Vogel, H.J. and Weljie A.M. (2012) "Satiety hormone and metabolomic response to an intermittent high energy diet differs in rats consuming long term diets high in protein or prebiotic fibre" J.Proteome Res. 11: 4065-4074.
Palmnäs, M.S.A. and Vogel, H.J. (2013) "The future of NMR metabolomics in cancer therapy: towards personalizing treatment and developing targeted drugs?" Metabolites 3: 373-396.
Krewulak, K., Bergmann, E.M. and Vogel, H.J. (2012) "Site directed mutagenesis studies and the crystal structure of the apo-form of the siderophore binding protein FhuD reveal a potential mechanism for ferric-hydroxamate binding" Biometals
Liu, Z., Garcia-Diaz, B., Catacchio, B., Chiancone, E. and Vogel, H.J. (2012) "The Pseudomonas aeruginosa inhibitor of vertebrate lysozyme exhibits a lower affinity for human lysozyme than its homolog from Escherichia coli" PLoS One
10. D. Breitkreutz, L. Hlatky, E. A. Rietman, and J. A. Tuszynski, Molecular Signaling Network Complexity Is Correlated with Cancer Patient Survivability, Proceedings of the National Academy of Sciences of the USA 109(23):9209-12 (2012) IF=9.77
19.K. Barakat, M. Gajewski and J.A. Tuszynski, DNA repair inhibitors: The next major step to improve cancer chemotherapy, Current Topics in Medicinal Chemistry 12(12):1367-90 (2012) IF=4.112
J. C. Knight, M. Wuest, F. A. Saad, M. Wang, D. W. Chapman, H.-S. Jans, S. E. Lapi, B. M. Kariuki, A. J. Amoroso, F. Wuest. Synthesis, characterisation and evaluation of a novel copper-64 complex with uptake on EMT-6 cells under hypoxic conditions. Dalton Transactions. 2013, 42, 12005-12014.
C. Mamat, A. Flemming, M. Köckerling, J. Steinbach, F. Wuest. Pd-catalyzed cross coupling of selected iodophenyl esters with HPPh2 for the synthesis of benzoate-functionalized phosphanes as novel building blocks for the traceless Staudinger Ligation. Synthesis. 2009, 19, 3311-3321.
Job Titles:
- Fellow of the National Institute for Nanotechnology of Canada
Dr. Tuszynski is a Fellow of the National Institute for Nanotechnology of Canada. He is an Allard Chair and Professor in Experimental Oncology in the Department of Oncology at the University of Alberta's Cross Cancer Institute and a Professor in the Department of Physics. Professor Jack Tuszynski received his M.Sc. with distinction in Physics from the University of Poznan (Poland) in 1980. He received his PhD in Condensed Matter Physics from the University of Calgary in 1983. He was a Post-Doctoral Fellow at the University of Calgary's Chemistry Department in 1983. He was an Assistant Professor at the Department of Physics of the Memorial University of Newfoundland from 1983 to 1988, and at the University of Alberta's Physics Department from 1988 to 1990. He became an Associate Professor from 1990 to 1993 and a Full Professor in 1993. He joined the Division of Experimental Oncology at the Cross Cancer Institute as the Allard Chair in 2005. He is on the editorial board of a number of international journals including the Journal of Biological Physics, Journal of Biophysics and Structural Biology (JBSB), Quantum Biosystems, Research Letters in Physics, Water: a Multidisciplinary Research Journal and Interdisciplinary Sciences-Computational Life Sciences. He is an Associate Editor of The Frontiers Collection, Springer-Verlag, Heidelberg. He had visiting professorships in Germany, Denmark, France, Belgium, Israel and China. He has published over 320 peer-reviewed papers, over 50 conference proceedings, 10 book chapters and 10 books; delivered over 400 scientific talks (including 150+ invited talks) on five continents. His research has been supported by numerous research grants from Canadian, US and European funding agencies. In 2005 he was appointed to the prestigious Allard Research Chair in Oncology at the University of Alberta. The $3 million Chair is supported by the Alberta Cancer Foundation and the Allard Foundation.
Job Titles:
- Department of Oncology / University of Calgary
- Radiation Oncologist, Clinical Associate Professor, Division of Radiation Oncology University [ ] View Profile
Dr. Wu graduated from the University of British Columbia Faculty of Medicine in 1993. Upon completion of radiation oncology residency training there in 1998, he continued further training for 18 months as a clinical fellow in genitourinary and palliative oncology at the Princess Margaret Hospital. Thereafter, he became staff radiation oncologist at the Hamilton Regional Cancer Centre, where he worked two and a half years before relocating to Calgary in 2002. Since then, he has continued his clinical practice at the Tom Baker Cancer Centre. His clinical focus is palliative care in oncology, metastatic cancer to bone, metastatic cancer to brain, and prostate cancer.
He completed a MSc. in Clinical Epidemiology at the University of Toronto in 2007. Within the post-graduate, academic setting, he was exposed to a wide spectrum of research methods in health services, measurement and economics, as well as knowledge translation. His current research activities include outcomes evaluation, research methodology, biostatistical methods, and research ethics.
In the 10+ years as clinical radiation oncologist at the Tom Baker Cancer Centre, Dr. Wu participated in various national committees, such as the Royal College Examination Board in Radiation Oncology, the NCIC Clinical Trials Group Symptom Control Executive Committee, and the Canadian Association of Radiation Oncology scientific meeting committee. Since 2011, he has been serving as associate chair for Alberta Cancer Research ethics Committee (changed to HREBA Cancer Committee in 2014).
Job Titles:
- Research Associate
- Research Group
I am Research Associate with Dr. John Lewis (University of Alberta). My main work areas include (1) preclinical development of novel biomarkers for prostate cancer screening and diagnosis, (2) small molecule library screening for various cancer therapeutic applications and (3) preclinical development of a liposomal / nanoparticle drug delivery platform.
My main focus is the development of prostate cancer microparticle biomarkers. We have identified new markers which are used in a "liquid biopsy" to detect and enumerate microparticles which are not only prostate cancer specific, but also indicative of disease status (e.g. normal, benign or metastatic). We are currently working on both retrospective and prospective sample analyses to further validate this assay but also and in collaboration with others, to identify and develop new prostate cancer specific biomarkers using proteomics, metabolomics and genetics.
While my main focus is the development of a liquid biopsy for prostate cancer microparticle biomarkers, my broad interest lies with assay and platform development for preclinical applications. In the Lewis lab we utilize many standard assay protocols but we are known for the development and use of the ex ovo chicken embryo model, also known as the chorioallantoic membrane or CAM model. This model system is used for investigating angiogenesis, metastasis, tumor biology, tumor vascular permeability, and nanoparticle, imaging agent and drug delivery. This model has permitted us to investigate and develop many imaging agents, biomarkers, antibodies, small molecule drugs with real time, and quantitative analyses under in vivo conditions. Much of my previous work was spent developing a real time, intravital tumor vascular permeability assay in the CAM model system.
John Lewis' research group was out in force; represented by John Lewis, Catalina Vasquez, Arun Raturi, Perrin Beatty and Abbie Coros. Despite the fact that, as one of the run/walk organizers Doug Mitchell pointed out to the participants, John ran in 15-year-old tennis shoes, the Lewis group runners ran well and had a great time!
Funds raised by the Terwillegar Trail Run and Walk go to support cancer research in Alberta. Check out the Alberta Cancer Foundations' "Dollars at Work" to read about how these funds have been used to support the research from APCaRI members Dr. Frank Wuest and Dr. John Lewis' labs!
Job Titles:
- Broadhurst DI, Ellis DI, Goodacre R, Kell DB
Kaderbhai NN, Broadhurst DI, Ellis DI, Goodacre R, Kell DB: Functional genomics via metabolic footprinting: monitoring metabolite secretion by Escherichia coli tryptophan metabolism mutants using FT-IR and direct injection electrospray mass spectrometry. Comp Funct Genomics 2003, 4(4):376-391.
Job Titles:
- Research Scientist at Alberta Health Services, Department of Population Health [ ]
Dr. Kopciuk obtained her PhD in Statistics from the University of Waterloo in Waterloo, Ontario in 2001 followed by a post-doctoral fellowship at the Samuel Lunenfeld Research Institute in Toronto, Ontario in Statistical Genetics. Dr. Kopciuk has expertise in experimental study designs including retrospective and prospective cohort designs. In addition, she has expertise in estimating sample sizes for discovery and validation phases of biomarker research.
Job Titles:
- Department of Oncology / University of Alberta
- Research Associate and Lab Manager, Dr. John Lewis Laboratory, Department [ ]
Leong HS, Robertson AE, Stoletov K, Leith SJ, Chin CA, Chien AE, Hague MN, Ablack A, Carmine-Simmen K, McPherson VA, Postenka CO, Turley EA, Courtneidge SA, Chambers AF, Lewis JD. Invadopodia are required for cancer cell extravasation and are a therapeutic target for metastasis. Cell Rep. 2014 Sep 11;8(5):1558-70.
Wentzell JS, Bolkan BJ, Carmine-Simmen K, Swanson TL, Musashe DT, Kretzschmar D. Amyloid precursor proteins are protective in Drosophila models of progressive neurodegeneration. Neurobiol Dis. 2012 Apr;46(1):78-87
Job Titles:
- Graduate Student at Dr. Zijlstra 's Lab, Vanderbilt University
- Graduate Student at Dr. Zijlstra 's Lab, Vanderbilt University Kate Began [ ]
Job Titles:
- Department of Oncology / University of Calgary / Rockyview General Hospital
- Pathologist, Professor, Department of Pathology and Laboratory Medicine University of [ ]
Kiril Trpkov, MD, is a Full Professor in the Department of Pathology and Laboratory Medicine at the Faculty of Medicine, University of Calgary in Calgary, Alberta, Canada. He is a Fellow of the Royal College of Physicians and Surgeons of Canada (FRCPC) and a consultant in urologic pathology for the Southern Alberta Institute of Urology and the Tom Baker Cancer Center in Calgary, Canada. During the last decade, Dr. Trpkov has established the Anatomical Pathology Laboratory at the Rockyview General Hospital in Calgary, Alberta into one of the largest centralized uropathology centres in Canada and North America. This unique set-up provides an excellent clinical service in uropathology and also provides an ideal environment for research and teaching.
Dr. Trpkov's areas of expertise and research focus include urological pathology and native kidney and transplant pathology. Dr. Trpkov has published over 60 peer-reviewed articles, several book chapters and other scholarly contributions, over 80 peer-reviewed abstracts and has presented more than 100 papers at national and international meetings. More recently, he has been a member of the organizing commitee for the annual International Society of Urologic Pathology (ISUP) scientific companion meeting (held in conjuction with the USCAP) and he has moderated this meeting from 2011-2013 together with Dr. Cristina Magi-Galluzzi. With Dr. Ming Zhou, he is a currently a Co-convener for the GU pathology program for the IAP 2014 Congress in Bangkok, Thailand. He is a also member of the USCAP Education committee and he is currently involved as a uropathology expert with several national or international panels establishing guidelines in uropathology. He has been invited to speak at many national and international meetings and has received several awards for his work. His featured at the Great teachers at the University of Calgary Web-site http://greatteachers.ucalgary.ca.
He is an avid movie and sports buff (downhill skiing, cycling, swimming, yoga, gym training) and his main current hobby is travelling to far away places.
Job Titles:
- Broadhurst DI, Davidson RL, Viant MR
Kirwan JA, Broadhurst DI, Davidson RL, Viant MR: Characterising and correcting batch variation in an automated direct infusion mass spectrometry (DIMS) metabolomics workflow. Anal Bioanal Chem 2013, 405(15):5147-5157.
Job Titles:
- Department of Oncology / University of Alberta
- Research Associate, Dr. John Lewis Laboratory, Department of Oncology, University [ ]
Wang, T., H. Abou-Ouf, S. A. Hegazy, M. Alshalalfa, K. Stoletov, J. Lewis, B. Donnelly and T. A. Bismar (2016). "Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients." J Mol Med (Berl) 94(12): 1411-1422.
Job Titles:
- Instructor
- Instructor, Cummings School of Medicine, University of Canada Dr. Willets [ ]
Lian is a faculty member in the Department of Cell Biology and Anatomy, and teaches clinically-oriented anatomy in Undergraduate Medical Education program, Bachelor of Health Science program and Graduate Science Education.
M. Wuest, B. J. Trayner, T. N. Grant, H.-S. Jans, J. Mercer, D. Murray, F. G. West, A. J. McEwan, F. Wuest, C. I. Cheeseman. Radiopharmacological evaluation of 6-deoxy-6-[18F]fluoro-D-fructose as a radiotracer for PET imaging of GLUT5 in breast cancer. Nucl. Med. Biol. 2011, 38, 461-475.
Madison is the lead research assistant/Data Entry Clerk for the APCaRI project at the Prostate Cancer Centre. She is responsible for maintaining the database for Calgary. Madison has a Bachelor's degree from the University of Western Ontario specializing in Medical Sciences. She intends to go back to school in the near future to obtain a medical degree. She hopes to continue to be involved in research throughout her future in the medical profession.
Dr. Michael Kolinsky is a PhD and MD in Edmonton, […]
Job Titles:
- Pathologist, Associate Professor, Department of Laboratory Medicine and Pathology University [ ]
Job Titles:
- Assistant Professor, University of Toronto, the Ontario Institute for Cancer [ ]
Job Titles:
- Medical Oncologist, Professor, Department of Medical Oncology, University of Alberta, [ ]
R. Li, W. Fan, G. Tian, H. Zhu, L. He, J. Cai, Q. Huang, Q. Cai, B. Li, Y .Bai, et al. Jan 2010. The sequence and de novo assembly of the giant panda genome. Nature 463: 311-317. [Cover Story] [F1000 Score 3] PMID: 20010809
J. Li, Z. Zhang, S. Vang, J. Yu, G.K. Wong‡, J. Wang‡. Apr 2009. Correlation between Ka/Ks and Ks is related to substitution model and evolutionary lineage. J. Mol. Evol. 68: 414-423. PMID: 19308632
Richter, M. Wuest, C. N. Bergman, J. D. Way, Stephanie Krieger, B. E. Rogers, F. Wuest. Re-routing the metabolic pathway of 18F-labelled peptides: The influence of prosthetic groups. Bioconjugate Chem. 2015, 26, 201-212.
Job Titles:
- Postdoctoral Fellow, Dr. John Lewis Laboratory and Dr. Roger Zemp
Andries Zijlstra*, Ronald T. Aimes*, Dan Zhu, Karine Regazzoni, Marco Seandel, Elena I. Deryugina and James P. Quigley. (2004) Collagenolysis-dependent angiogenesis mediated by matrix metalloproteinase-13 (collagenase-3). Journal of Biological Chemistry, 279(26): 27633-45. (PMID: 15066996)
Job Titles:
- Professor and Founding Scientific Director of the Alberta Innovates Centre [ ]
Job Titles:
- Postdoctoral Fellow, Dr. Zijlstra 's Lab, Vanderbilt University Dr. Arnold Started
- Research Fellow in the Laboratory of Dr. Zijlstra
Dr. Arnold started as a graduate student in the laboratory of Rolf Brekken at UT Southwestern, where she studied the role of the tumor microenvironment in cancer progression and metastasis. Her specific research emphasis was then, and now, on molecular mechanisms that control tumor progression.
Dr. Arnold is currently a postdoctoral research fellow in the laboratory of Dr. Zijlstra at Vanderbilt University where her projects focus on tumor cell adhesion, migration and metastasis. She spearheads the translation of these mechanistic findings to the development of clinically relevant biomarkers. The current focus is on the clinical relevance of a cell adhesion molecule, ALCAM, and the mechanism by which is controls motility.
Postdoctoral Fellow, Dr. Zijlstra's Lab, Vanderbilt University Dr. Arnold started […]
Job Titles:
- Department of Oncology / University of Alberta
- Graduate Student ( M.Sc. ), Dr. John Lewis Laboratory, Department of Oncology, [ ]
Job Titles:
- Biostatistician, Assistant Clinical Professor, Department of Medical Oncology, University of [ ]
Job Titles:
- Pathologist, Clinical Associate Professor
Job Titles:
- Dean Ruether, Lorna M Weir, Debjani Grenier, & Lesley F Degner. Study Protocol
Thomas F Hack, J Dean Ruether, Lorna M Weir, Debjani Grenier, & Lesley F Degner. Study protocol: Addressing evidence and context to facilitate transfer and uptake of consultation recording use in oncology: A knowledge translation implementation study. Implementation Science 2011, 6:20. doi:10.1186/1748-5908-6-20
Tietz, M. Wuest, A. Marshall, M. Wang, C. Bergman, J. Way, F. Wuest. PET imaging of cyclooxygenase-2 (COX-2) in a colon cancer model. J. Nucl. Med. Submitted.
Job Titles:
- Manager, Alberta Prostate Cancer Registry, Prostate Cancer Centre, Calgary, AB [ ]
F. Wuest, V. Bouvet, BaoChan Mai, P. LaPointe. Fluorine- and rhenium-containing geldanamycin derivatives as leads for the development of molecular probes for imaging Hsp90. Org. Biomol. Chem. 2012, 10, 6724-6731.
V. R. Bouvet, M. Wuest, L. I. Wiebe, F. Wuest. Synthesis of hypoxia imaging agent 1-(5-deoxy-5-fluoro-a-D-arabinofuranosyl)-2-nitroimidazole [18F]FAZA using microfluidic technology. Nucl. Med. Biol. 2011, 38, 335-345.
Job Titles:
- Department of Cancer Biology
Wuest, A. Perrault, J. Kapty, S. Richter, C. Foerster, C. Bergman, J. Way, J. Mercer, F. Wuest. Radiopharmacological evaluation of 18 F-labeled phosphatidylserine-binding peptides for molecular imaging of apoptosis. Nucl. Med. Biol. 2015, 42, 864-74.